ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 1539 • ACR Convergence 2025

    The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis

    Muhammad Usman Hashmi1, Paramarajan Piranavan2, Yasmeen Sufi3, Zaira Nasir4, Zainab Azhar5, Shamaem Tariq5, Hamas Ul Hudaibia5, IMRAN SAEED6, Aayet Zulfiqar5, Natasha Rasool2 and Anum Faiz7, 1Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, 2University of Kentucky, Louisville, KY, 3Karachi Medical & Dental College, Karachi, Karachi, Pakistan, 4Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, 5Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, 6Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, 7Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan

    Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…
  • Abstract Number: 2418 • ACR Convergence 2025

    ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin

    Mehrnaz Gharaee-Kermani1, Svenja Henning2, John LaCava3, Tomas Mustelin4 and J. Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2University of Groningen, Groningen, Groningen, Netherlands, 3Rockefeller University, New York City, NY, NJ, 4University of Washington, Seattle, WA

    Background/Purpose: Type I interferons (IFNs) are elevated in the skin and blood of patients with systemic (SLE) and cutaneous (CLE) lupus erythematosus. Upregulation of type…
  • Abstract Number: 0617 • ACR Convergence 2025

    Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera

    Kathryn Counts1, Dulaney Wilson2, Leon Furchtgott3 and Gary Gilkeson1, 1Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, 3SeraNova Bio, Boston, MA

    Background/Purpose: Key features in the pathophysiology of SLE include cytokine dysregulation and autoantibody production. Traditional autoantibody testing in SLE is primarily limited to intracellular antigens…
  • Abstract Number: 1655 • ACR Convergence 2025

    Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation

    Sandra Williams1, Soyeong Sim2 and Sandra Wolin2, 1National Institute of Arthritis, Musculoskeletal and Skin Diseases; National Cancer Institute, Bethesda, MD, 2National Cancer Institute, Frederick, MD

    Background/Purpose: Extracellular vesicles (EVs) are small structures that enclose a variety of nucleic acids. While much of the published work on EV RNA has focused…
  • Abstract Number: 2451 • ACR Convergence 2025

    Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus

    Amy Hurst1, Mehrnaz Gharaee-Kermani1, Yuli Cai2, Rachael Bogle3, Lin Zhang1, Amber Young2, Craig Dobry1, Srilakshmi Yalavarthi1, Jason S. Knight1, Johann Gudjonsson2, Alex Tsoi3, Patricia Rohan4, Angela Kibiy5, Karen Boyle6, Margie Byron7, Laura Baird7 and J. Michelle Kahlenberg1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, 3University of Michigan, Holland, OH, 4NIH, Bethesda, MD, 5NIH/NIAID, Rockville, MD, 6Rho, Inc, Durham, NC, 7Rho, Inc., Durham, NC

    Background/Purpose: Photosensitivity lowers quality of life in patients with cutaneous lupus erythematosus (CLE) and puts patients with systemic lupus erythematosus (SLE) at risk of systemic…
  • Abstract Number: 0631 • ACR Convergence 2025

    Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India.

    Rudrarpan Chatterjee1, Komal Singh2, Ranjan Gupta3, Sudhir Sinha4 and Amita Aggarwal5, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, 3All India Institute of Medical Sciences, New Delhi, Delhi, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, 5Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are predisposed to infections due to immune dysregulation. Autoantibodies to cytokines can cause serious infections, including severe COVID-19,…
  • Abstract Number: 1668 • ACR Convergence 2025

    A clinically validated assay for rapid determination of type I and type II interferon activity in pediatric inflammatory diseases

    Evan Hsu1, Courtney Leson2, Amrita Basu3, Michael Lam4, Jian Yue4, Casey Rimland5, Rachel Weng4, Lauren Henderson6, Joyce Chang2, Mary Beth Son4, Fatma Dedeoglu4, roshini Abraham3 and Pui Lee1, 1Boston Children's Hospital, Newton, MA, 2Boston Children's Hospital, Boston, 3Nationwide Children's Hospital, Columbus, OH, 4Boston Children's Hospital, Boston, MA, 5Brigham and Women's Hospital, Boston, 6Boston Children's Hospital, Watertown, MA

    Background/Purpose: Type I interferons (IFN-I) and type II interferon (IFN-g) are essential to host defense but dysregulated production of these cytokines is increasingly recognized in…
  • Abstract Number: 2497 • ACR Convergence 2025

    Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution

    Pietro Bearzi1, Elena Pachera2, Astrid Hofman3, Laura Much4, Lumeng Li1, Kristina Bürki3, Cosimo Bruni5, Mike Becker6, Anna-Maria Hoffmann-Vold7, Roberto Giacomelli8 and Oliver Distler9, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 4Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 5University of Zurich, Zurich, Switzerland, 6Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 7Oslo University Hospital, Oslo, Norway, 8i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, 9Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Autoimmunity is a hallmark of SSc pathogenesis. Emerging evidence suggests that interferon (IFN) signaling plays a role in predicting SSc patients at risk of…
  • Abstract Number: L01 • ACR Convergence 2024

    Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases

    Matthew Martin1, Erik Wilker1, Diana Gikunju1, Usha Narayanan1, Unnati Pandya1, Vijetha Prakash1, Ashley Edwards1, Sameer Kawatkar1, Tenghui Chen1, Ragunath Chandran1, Sai Sunder1, Sumathi Biradar1, Joerg Distler2, Alexandra Joseph1, Stephanos Ioannidis1 and Bhavatarini Vangamudi1, 1Exo Therapeutics, Cambridge, MA, 2Exo Therapeutics, Düsseldorf, Germany

    Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
  • Abstract Number: 0633 • ACR Convergence 2024

    Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus

    Wenyan Miao1, Digna de Bruin2, Cedric Arisdakessian1, Jannik Rousel2, Jared Steranka1, Matthijs Moerland2, Eric Jacobson1, Mehrnaz Gharaee-Kermani3, Liyang Diao1, Craig Dobry3, Nafeeza Hafeez1, Brian Desrosiers1, J. Michelle Kahlenberg3, Heike Keilhack1, Robert Rissmann2, Keith M Wilcoxen1 and Tessa Niemeyer-van der Kolk2, 1Rome Therapeutics, Boston, MA, 2Centre for Human Drug Research, Leiden, Netherlands, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
  • Abstract Number: 1537 • ACR Convergence 2024

    Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases

    Kelly A. Pike1, Nadine Fradet1, Samuel Gaudreault1, Alexander M Skeldon2, Ramsay E. Beveridge2, Patrick Cyr2, Nicolas Sgarioto2, Philippe Le Gros3, Eleftheria Seliniotakis2, Valerie Dumais2, Jacklyn Smith2, James I.P Stewart2, Mehrnaz Gharaee-Kermani4, Michelle J Kahlenberg4 and Michael A. Crackower2, 1Ventus Therapeutics, Saint-Laurent, QC, Canada, 2Ventus Therapeutics, Saint-Laurent, Canada, 3Ventus Therapeutics, Montreal, QC, Canada, 4University of Michigan, Ann Arbor, MI

    Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…
  • Abstract Number: 1828 • ACR Convergence 2024

    SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling

    Christopher Wasson1, Stefano Di Donato2, Rebecca Ross3, Vishal Kakkar4 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom, 4LIRMM University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis is an autoimmune disease which is characterized by fibrosis of the skin and the internal organs with variable severity. Type I interferon…
  • Abstract Number: 0666 • ACR Convergence 2024

    Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy

    Cuiling Fan1, Shixian Chen2 and Juan Li1, 1Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), 2Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
  • Abstract Number: 1553 • ACR Convergence 2024

    Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)

    Torsten Witte1, Ruth Fernandez Ruiz2, Nadezda Abramova3, Dominika Weinelt3, Flavie Moreau4, Lena Klopp-Schulze5, Jamie Shaw6, Deborah Denis7 and Joerg Wenzel8, 1Dept of Immunology and Rheumatology, Hannover, Germany, 2Global Clinical Development, EMD Serono, Billerica, MA, 3Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, 4Global Biostatistics, EMD Serono, Billerica, MA, 5Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, 6Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, 7EMD Serono, Rockland, MA, 8Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany

    Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
  • Abstract Number: 1831 • ACR Convergence 2024

    Role of Long Non-Coding RNA H19 in Mediating Skin Fibrosis in Systemic Sclerosis

    Begoña Caballero-Ruiz1, Christopher Wasson2, Rebecca Ross3 and Francesco Del Galdo2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) is an immune driven condition leading to skin fibrosis, as well as internal organs. Dermal fibroblasts are the key cellular elements…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology